Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Home About Us Pipeline News Investors Contacts Careers

Now Enrolling: A study of an investigational drug, Alisertib, in patients wih extensive stage small cell lung cancer.PUMA
RECENT NEWS RELEASE RECENT EVENTS CLINICAL TRIALS

Feb. 22, 2024 - Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
Read


Feb. 15, 2024 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Read

Feb. 13, 2024 - Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
Read

Jan. 11, 2024 - Puma Biotechnology to Present at B. Riley Securities 4 th Annual Oncology Conference
Read

Dec. 11, 2023 - Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Read

Nov. 2, 2023 - Puma Biotechnology Reports Third Quarter 2023 Financial Results
Read

Oct. 19, 2023 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
Read

Oct. 14, 2023 - Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
Read

Sept. 21, 2023 - Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
Read

Aug. 31, 2023 - Puma Biotechnology to Present at the H.C. Wainwright 25 th Annual Global Investment Conference
Read

Aug. 8, 2023 - Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
Read

Aug. 3, 2023 - Puma Biotechnology Reports Second Quarter Financial Results
Read

Upcoming Events


Mar. 6, 2024 - TD Cowen’s 44th Annual Health Care Conference
More



Past Events

Feb. 15, 2024 - Puma Biotechnology 4Q-2023 Financial Results Conference Call
More

Jan. 11, 2024 - B. Riley Securities 4th Annual Oncology Conference
More

Dec. 11, 2023 - Puma Biotechnology Corporate Presentation
More

Nov. 2, 2023 - Puma Biotechnology 3Q-2023 Financial Results Conference Call
More

Oct. 11-15, 2023 - AACR-NCI-EORTC International Conference
More
Puma-Sponsored Trials
Investigator-Sponsored Trials



Annual Report

2022 Annual Report

 Annual Report Archives


Contact

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com

Business Development:
info@pumabiotechnology.com

Investor Relations:
ir@pumabiotechnology.com

Follow Us: